Even though novel biologics dramatically improved the treatment of many diseases, many patient populations are still in need. The very high cost of biologics makes them unavailable to 95% of the world population. Resistances to monoclonal antibodies are so prevalent that only 25% of patients who can afford them are still under treatment after 2 years. Finally, many patients are reluctant to self-inject biologics twice a month, given their deleterious side-effects.
In comparison, Peptinov’s approach has major competitive advantages in many patient populations.
No resistance to treatment
Harnessing the patients’ own antibodies to treat the disease means no induction of antibodies (ADA: Anti-Drug Antibodies) against the treatment itself (vs. over 50% resistance against many biologics).
Easy to use
Non intravenous injections, the immunization schedule consists in three to four subcutaneous or intramuscular boosters per year, simple to monitor.
Extremely low production costs, a paradigm shift in treatment protocols. Because of their high costs, monoclonal antibodies are not given early enough during the initial phase of inflammatory diseases; this leads to irreversible joint destruction.
Low-priced immunotherapies would be given early in the course of the disease. They can also potentially take over monoclonal antibodies after the initial acute phase to maintain the health status over the long-term. Most world populations do not have access to highly priced monoclonal antibodies, an immunotherapy would be a revolution for very large populations in Eastern Europe, South America, Asia and Africa.
Large market potential
Peptinov’s peptide-based approach can potentially be applied to any protein, over different therapeutic areas. Large markets can be targeted by Peptinov’s immunotherapies.
For instance, IL-6 overproduction is involved in several chronic inflammatory diseases (osteoarthritis, rheumatoid arthritis, Horton’s disease, or in different cancers).